激光间质热疗治疗原发性和转移性脑肿瘤:系统综述与荟萃分析
该系统综述与荟萃分析纳入45项研究共826例患者,评估激光间质热疗(LITT)治疗原发性和转移性脑肿瘤的适应证、不良事件及1年无进展生存和总生存。结果显示操作相关不良事件合并发生率为30%,高级别胶质瘤1年无进展生存18.6%、1年总生存43.0%,脑转移瘤分别为51.2%和56.3%。作者认为LITT对选定患者总体安全,需未来设计良好的比较研究。
要点
- LITT操作相关不良事件合并发生率为30%,新发神经功能缺损和术后水肿最常见,但多为暂时性。
- 高级别胶质瘤1年无进展生存18.6%,1年总生存43.0%;脑转移瘤分别为51.2%和56.3%。
- LITT对选定患者总体安全,未来需设计良好的比较研究对比现行标准治疗。
核心结论
- 新发神经功能缺损和术后水肿是LITT后最常报告的不良事件,但多为暂时性。
- 该荟萃分析基于现有信息提供了进展和生存结局的最佳统计估计。
- LITT对选定患者总体是安全的手术,未来需开展设计良好的比较研究对比其结局与现行标准治疗。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library数据库至2021年10月。
- 纳入比较性和描述性研究,排除病例报告。
- 共45项研究符合纳入标准,826例患者纳入荟萃分析,共829个病灶。
主要发现
- 病灶分类:高级别胶质瘤361个,低级别胶质瘤116个,转移性脑肿瘤337个,非胶质肿瘤15个。
- 提供LITT的适应证包括:深部/不可及肿瘤(12项研究)、放射外科失败后的挽救治疗(9项)、≥2种治疗方案失败(3项)、儿童患者(4项)、患者偏好(1项);12项研究适应证不明确。
- 所有肿瘤的操作相关不良事件(轻微或严重)合并发生率为30%(95%CI,27%-40%)。
- 神经功能缺损(轻微或严重)合并发生率16%(12%-22%);术后水肿14%(8%-22%);癫痫发作6%(4%-9%);血肿20%(14%-29%);深静脉血栓19%(11%-30%);脑积水8%(5%-12%);伤口感染5%(3%-7%)。
- 1年无进展生存:高级别胶质瘤18.6%(11.3%-29.0%),4级星形细胞瘤16.9%(11.6%-24.0%),脑转移瘤51.2%(36.7%-65.5%)。
关键数值与推荐
- 1年总生存:高级别胶质瘤43.0%(36.0%-50.0%),4级星形细胞瘤45.9%(95%CI,37.9%-54%),低级别胶质瘤93.0%(42.3%-100%),脑转移瘤56.3%(47.0%-65.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laser interstitial thermal therapy (LITT) is a minimally invasive treatment option for intracranial tumors that are challenging to treat via traditional methods; however, its safety and efficacy are not yet well validated in the literature. The objectives of the study were to assess the available evidence of the indications and adverse events (AEs) of LITT and 1-year progression-free survival and 1-year overall survival in the treatment of primary and secondary brain tumors. METHODS: A comprehensive literature search was conducted through the databases PubMed, Embase, and the Cochrane Library until October 2021. Comparative and descriptive studies, except for case reports, were included in the meta-analysis. Separate analyses by tumor type (high-grade gliomas, including World Health Organization grade 4 astrocytomas [which include glioblastomas] as a specific subgroup; low-grade gliomas; and brain metastases) were conducted. Pooled effect sizes and their 95% confidence intervals (CI) were generated via random-effects models. RESULTS: Forty-five studies met the inclusion criteria, yielding 826 patients for meta-analysis. There were 829 lesions in total, of which 361 were classified as high-grade gliomas, 116 as low-grade gliomas, 337 as metastatic brain tumors, and 15 as nonglial tumors. Indications for offering LITT included deep/inaccessible tumor (12 studies), salvage therapy after failed radiosurgery (9), failures of ≥2 treatment options (3), in pediatric patients (4), patient preference (1); indications were nonspecific in 12 studies. Pooled incidence of all (minor or major) procedure-related AEs was 30% (95% CI, 27%-40%) for all tumors. Pooled incidence of neurologic deficits (minor or major) was 16% (12%-22%); postprocedural edema 14% (8%-22%); seizure 6% (4%-9%); hematoma 20% (14%-29%); deep vein thrombosis 19% (11%-30%); hydrocephalus 8% (5%-12%); and wound infection 5% (3%-7%). One-year progression-free survival was 18.6% (11.3%-29.0%) in high-grade gliomas, 16.9% (11.6%-24.0%) among the grade 4 astrocytomas; and 51.2% (36.7%-65.5%) in brain metastases. One-year overall survival was 43.0% (36.0%-50.0%) in high-grade glioma, 45.9% (95% CI, 37.9%-54%) in grade 4 astrocytomas; 93.0% (42.3%-100%) in low-grade gliomas, and 56.3% (47.0%-65.3%) in brain metastases. CONCLUSIONS: New neurologic deficits and postprocedural edema were the most reported AEs after LITT, albeit mostly transient. This meta-analysis provides the best statistical estimates of progression and survival outcomes based on the available information. LITT is generally a safe procedure for selected patients, and future well-designed comparative studies on its outcomes versus the current standard of care should be performed.
引用
- Alkazemi M, Lo YT, Hussein H, et al. Laser Interstitial Thermal Therapy for the Treatment of Primary and Metastatic Brain Tumors: A Systematic Review and Meta-Analysis. World Neurosurg. 2022. PMID: 36549438. doi:10.1016/j.wneu.2022.12.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。